参考文献/References:
[1] Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors[J]. J Natl Cancer Inst, 2000, 92(3):205-216. DOI:10.1093/jnci/92.3.205.
[2] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:Revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247. DOI:10.1016/j.ejca.2008.10.026.
[3] Shankar LK, Van den Abbeele A, Yap J, et al. Considerations for the use of imaging tools for phase Ⅱ treatment trials in oncology[J]. Clin Cancer Res, 2009, 15(6):1891-1897. DOI:10.1158/1078-0432. CCR-08-2030.
[4] Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment:practical approaches and limitations[J]. Radiographics, 2008, 28(2):329-344. DOI:10.1148/rg.282075068.
[5] Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST:Evolving Considerations for PET Response Criteria in Solid Tumors[J]. J Nucl Med, 2009, 50(Suppl 1):S122-150. DOI:10.2967/jnumed. 108.057307.
[6] Juweid ME, Cheson BD. Positron-Emission Tomography and Assessment of Cancer Therapy[J]. N Engl J Med, 2006, 354(5):496-507. DOI:10.1056/NEJMra050276.
[7] World Health Organization. WHO handbook for reporting results of cancer treatment[R]. Geneva:WHO, 1979:1-45.
[8] Shang J, Ling X, Zhang L, et al. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer[J]. Eur J Nucl Med Mol Imaging, 2016, 43(11):1945-1953. DOI:10.1007/s00259-016-3420-7.
[9] Ordu C, Selcuk NA, Akosman C, et al. Comparison of metabolic and anatomic response to chemotherapy based on PERCIST and RECIST in patients with advanced stage non-small cell lung cancer[J]. Asian Pac J Cancer Prev, 2015, 16(1):321-326. DOI:10.7314/APJCP.2015.16.1.321.
[10] Ding Q, Cheng X, Yang L, et al. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer:PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST)[J]. J Thorac Dis, 2014, 6(6):677-683. DOI:10.3978/j.issn.2072-1439.2014.05.10.
[11] Tahari AK, Chien D, Azadi JR, et al. Optimum lean body formulation for correction of standardized uptake value in PET imaging[J]. J Nucl Med, 2014, 55(9):1481-1484. DOI:10.2967/jnumed.113.136986.
[12] Rubello D, Gordien P, Morliere C, et al. Variability of Hepatic 18F-FDG Uptake at Interim PET in Patients With Hodgkin Lymphoma[J]. Clin Nucl Med, 2015, 40(8):e405-e410. DOI:10.1097/RLU.0000000000000828.
[13] Yoon DH, Baek S, Choi CM, et al. FDG-PET as a potential tool for selecting patients with advanced non-small cell lung cancer who may be spared maintenance therapy after first-line chemotherapy[J]. Clin Cancer Res, 2011, 17(15):5093-5100. DOI:10.1158/1078-0432.CCR-10-2791.
[14] Kishimoto M, Iwano S, Ito S, et al. Prognostic evaluations of small size lung cancers by 18F-FDG PET/CT and thin-section CT[J]. Lung Cancer, 2014, 86(2):180-184. DOI:10.1016/j.lungcan.2014.09.006.
[15] Cistaro A, Quartuccio N, Mojtahedi A, et al. Prediction of 2 years-survival in patients with stage Ⅰ and Ⅱ non-small cell lung cancer utilizing 18F-FDG PET/CT SUV quantification[J]. Radiol Oncol, 2013, 47(3):219-223. DOI:10.2478/raon-2013-0023.
[16] Billè A, Okiror L, Skanjeti A, et al. The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients:Analysis of 413 cases[J]. Clin Lung Cancer, 2013, 14(2):149-156. DOI:10.1016/j.cllc.2012.04.007.
[17] Hyun SH, Ahn HK, Kim H, et al. Volume-based assessment by 18F-FDG PET/CT predicts survival in patients with stage Ⅲ non-small-cell lung cancer[J]. Eur J Nucl Med Mol Imaging, 2014, 41(1):50-58. DOI:10.1007/s00259-013-2530-8.
[18] Chung HW, Lee KY, Kim HJ, et al. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma[J]. J Cancer Res Clin Oncol, 2014, 140(1):89-98. DOI:10.1007/s00432-013-1545-7.
[19] Takada K, Toyokawa G, Okamoto T, et al. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18F-fluorodeoxyglucose positron emission tomography/computed tomography[J]. Cancer Med, 2017, 6(11):2552-2561. DOI:10.1002/cam4.1215.
[20] van Gool MH, Aukema TS, Schaake EE, et al. Timing of Metabolic Response Monitoring During Erlotinib Treatment in Non-Small Cell Lung Cancer[J]. J Nucl Med, 2014, 55(7):1081-1086. DOI:10.2967/jnumed.113.130674.
[21] Derlin T, Jonigk D, Bauersachs J, et al. Molecular Imaging of Chemokine Receptor CXCR4 in Non-Small Cell Lung Cancer Using 68Ga-Pentixafor PET/CT:Comparison With 18F-FDG[J]. Clin Nucl Med, 2016, 41(4):e204-e205. DOI:10.1097/RLU.00000000-00001092.
[22] Vu CC, Matthews R, Kim B, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis from 18F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage Ⅰ non-small-cell lung cancer[J]. Nucl Med Commun, 2013, 34(10):959-963. DOI:10.1097/MNM.0b013e32836491a9.
[23] Soussan M, Chouahnia K, Maisonobe JA, et al. Prognostic implications of volume-based measurements on FDG PET/CT in stage Ⅲ non-small-cell lung cancer after induction chemotherapy[J]. Eur J Nucl Med Mol Imaging, 2013, 40(5):668-676. DOI:10.1007/s00259-012-2321-7.
[24] Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT:EANM procedure guidelines for tumour imaging:version 2.0[J]. Eur J Nucl Med Mol Imaging, 2015, 42(2):328-354. DOI:10.1007/s00259-014-2961-x.
[25] Bhoil A, Singh B, Singh N, et al. Can 3’-deoxy-3’-18F-fluorothymidine or 2’-deoxy-2’-18F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results[J]. Hell J Nucl Med, 2014, 17(2):90-96. DOI:10.1967/s002449910136.
[26] Yanagawa M, Tatsumi M, Miyata H, et al. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer:PET response criteria in solid tumors versus response evaluation criteria in solid tumors[J]. J Nucl Med, 2012, 53(6):872-880. DOI:10.2967/jnumed.111.098699.
[27] Liao S, Penney BC, Zhang H, et al. Prognostic Value of the Quantitative Metabolic Volumetric Measurement on 18F-FDG PET/CT in Stage Ⅳ Nonsurgical Small-cell Lung Cancer[J]. Acad Radiol, 2012, 19(1):69-77. DOI:10.1016/j.acra.2011.08.020.
[28] Moon SH, Cho SH, Park LC, et al. Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy[J]. Eur J Nucl Med Mol Imaging, 2013, 40(7):1005-1013. DOI:10.1007/s00259-013-2400-4.
[29] Hyun SH, Choi JY, Kim K, et al. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection[J]. Ann Surg, 2013, 257(2):364-370. DOI:10.1097/SLA.0b013e318262a6ec.
[30] Lee JW, Lee SM, Yun M, et al. Prognostic value of volumetric parameters on staging and posttreatment FDG PET/CT in patients with stage Ⅳ non-small cell lung cancer[J]. Clin Nucl Med, 2016, 41(5):347-353. DOI:10.1097/RLU.0000000000001126.
[31] Satoh Y, Onishi H, Nambu A, et al. Volume-based Parameters Measured by Using FDG PET/CT in Patients with Stage Ⅰ NSCLC Treated with Stereotactic Body Radiation Therapy:Prognostic Value[J]. Radiology, 2014, 270(1):275-281. DOI:10.1148/radiol.13130652.
[32] van Gool MH, Aukema TS, Hartemink KJ, et al. FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC[J]. World J Radiol, 2014, 6(7):392-398. DOI:10.4329/wjr.v6.i7.392.
[33] Rizzo G, Cattaneo GM, Castellone P, et al. Multi-modal medical image integration to optimize radiotherapy planning in lung cancer treatment[J]. Ann Biomed Eng, 2004, 32(10):1399-1408. DOI:10.1114/B:ABME.0000042227.37183.1c.
[34] Mah K, Caldwell CB, Ung YC, et al. The impact of 18FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma:a prospective study[J]. Int J Radiat Oncol Biol Phys, 2002, 52(2):339-350. DOI:10.1016/S0360-3016(01)01824-7.
[35] Mattoli MV, Massaccesi M, Castelluccia A, et al. The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment:low-dose fractionated radiotherapy with concurrent chemotherapy[J/OL]. Radiat Oncol, 2017, 12(1):4[2017-12-14]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217210. DOI:10.1186/s13014-016-0737-0.
[36] Weber WA. Assessing Tumor Response to Therapy[J]. J Nucl Med, 2009, 50 Suppl 1:S1-10. DOI:10.2967/jnumed.108.057174.
[37] Lee YJ, Cho A, Cho BC, et al. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer[J]. Clin Cancer Res, 2009, 15(7):2426-2432. DOI:10.1158/1078-0432.CCR-08-2258.
[38] 丁重阳,郭喆,李洋洋,等. 18F-FDG PET-CT在广泛期小细胞肺癌预后判断中的价值[J]. 中华肿瘤杂志, 2017, 39(11):828-834. DOI:10.3760/cma.j.issn.0253-3766.2017.11.005. Ding CY, Guo Z, Li YY, et al. Prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer[J]. Chin J Oncol, 2017, 39(11):828-834.
[39] Zer A, Domachevsky L, Rapson Y, et al. The Role of 18F-FDG PET/CT on Staging and Prognosis in Patients with Small Cell Lung Cancer[J]. Eur Radiol, 2016, 26(9):3155-3161. DOI:10.1007/s00330-015-4132-2.
[40] Park S, Lee E, Rhee S, et al. Correlation between Semi-Quantitative 18F-FDG PET/CT Parameters and Ki-67 Expression in Small Cell Lung Cancer[J]. Nucl Med Mol Imaging, 2016, 50(1):24-30. DOI:10.1007/s13139-015-0363-z.
相似文献/References:
[1]麦卫平,张永林.能谱CT成像在肺癌诊断中的应用研究进展[J].国际放射医学核医学杂志,2016,40(1):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
Mai Weiping,Zhang Yonglin.Research progress of spectral imaging in the diagnosis of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
[2]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[3]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[4]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[5]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[6]许靖,李肖红,秦永德,等.帕金森病脑部葡萄糖代谢和脑多巴胺转运体PET显像特点的临床研究[J].国际放射医学核医学杂志,2016,40(5):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
Xu Jing,Li Xiaohong,Qin Yongde,et al.Clinical study of brain glucose metabolism and brain dopamine transporter PET imaging in patients with Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
[7]霍小东,王慧星,阎卫亮,等.血管内皮抑制素对125I近距离照射裸鼠肺癌移植瘤的增敏效应研究[J].国际放射医学核医学杂志,2016,40(5):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
Huo Xiaodong,Wang Huixing,Yan Weiliang,et al.Sensitization effect of endostatin for 125I brachytherapy on transplanted tumor in nude mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
[8]曹登敏,林美福,陈文新,等.继发性骨淋巴瘤的18F-FDG PET/CT影像学表现[J].国际放射医学核医学杂志,2016,40(6):403.[doi:10.3760/cma.j.issn.1673-4114.2016.06.001]
Cao Dengmin,Lin Meifu,Chen Wenxin,et al.Analysis on 18F-FDG PET/CT imaging characteristics in secondary bone lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):403.[doi:10.3760/cma.j.issn.1673-4114.2016.06.001]
[9]李生栩,唐明灯,林端瑜,等.18F-FDG PET/CT在胸段食管鳞癌淋巴结转移中的诊断价值[J].国际放射医学核医学杂志,2016,40(6):408.[doi:10.3760/cma.j.issn.1673-4114.2016.06.002]
Li Shengxu,Tang Mingdeng,Lin Duanyu,et al.Value of 18F-FDG PET/CT in detecting metastatic lymph nodes of thoracic esophageal squamous cell carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):408.[doi:10.3760/cma.j.issn.1673-4114.2016.06.002]
[10]张莹莹,王振光,武凤玉,等.特发性肺间质纤维化HRCT病变区与非病变区18F-FDG PET/CT表现分析[J].国际放射医学核医学杂志,2016,40(6):414.[doi:10.3760/cma.j.issn.1673-4114.2016.06.003]
Zhang Yingying,Wang Zhenguang,Wu Fengyu,et al.18F-FDG PET/CT imaging analysis of regions with abnormal and normal pulmonary parenchyma on high resolution CT in idiopathic pulmonary fibrosis patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):414.[doi:10.3760/cma.j.issn.1673-4114.2016.06.003]
[11]付畅,史大鹏,徐俊玲,等.不同组织学类型肺癌患者大脑静息葡萄糖代谢改变研究[J].国际放射医学核医学杂志,2014,38(2):75.[doi:10.3760/cma.j.issn.1673-4114.2014.02.002]
Fu Chang,Shi Dapeng,Xu Junling,et al.The preliminary study of brain glucose metabolism changes in patients with lung cancer of different histological types[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):75.[doi:10.3760/cma.j.issn.1673-4114.2014.02.002]
[12]杨小丰,居热提·阿扎提,曹务成,等.肺癌患者体重、血糖浓度和病灶大小对18F-FDG PET/CT病灶SUV的影响[J].国际放射医学核医学杂志,2013,37(4):211.[doi:10.3760/cma.j.issn.1673-4114.2013.04.006]
YANG Xiao-feng,JURETI-Azhati,CAO Wu-cheng,et al.The effect of lung cancer patients’ weight, blood glucose concentration and lesion size of lung cancer on 18F-FDG PET/CT lesions SUV results[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):211.[doi:10.3760/cma.j.issn.1673-4114.2013.04.006]
[13]李乐保,彭翔,叶慧,等.18F-FDG PET-CT对周围型肺癌的诊断价值研究[J].国际放射医学核医学杂志,2010,34(4):209.[doi:10.3760/cma.j.issn.1673-4114.2010.04.005]
LI Le-bao,PENG Xiang,YE Hui,et al.The diagnostic value of PET-CT on peripheral lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(4):209.[doi:10.3760/cma.j.issn.1673-4114.2010.04.005]
[14]田亚东,袁卫红.影像学及肿瘤相关抗原在诊断肺癌中的应用[J].国际放射医学核医学杂志,2011,35(5):295.[doi:10.3760/cma.j.issn.1673-4114.2011.05.011]
TIAN Ya-dong,YUAN Wei-hong.Application of imaging and tumor-associated antigen in the diagnosis of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):295.[doi:10.3760/cma.j.issn.1673-4114.2011.05.011]
[15]李亚军,白人驹,高硕,等.兔VX2肺肿瘤PET-CT与血管生成的相关性研究[J].国际放射医学核医学杂志,2010,34(3):139.
LI Ya-jun,BAI Ren-ju,GAO Shuo,et al.The correlation between PET-CT imaging and microvessed density in rabbit lung VX2 tumor model[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(4):139.
[16]任树华,华逢春,赵军.PET-CT乏氧显像及其在肺癌中的研究进展[J].国际放射医学核医学杂志,2008,32(5):286.
REN Shu-hua,HUA Feng-chun,ZHAO Jun.Advances of research on PET-CT hypoxia imaging in lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(4):286.
[17]孙建鹰,杜明华.18F-氟脱氧葡萄糖显像在肺癌治疗中应用价值的[J].国际放射医学核医学杂志,2008,32(5):290.
SUN Jian-yin,DU Ming-hua.The new advancement of application value of imaging techniques used 18F-fluorodeoxyglucose in therapy of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(4):290.
[18]柳卫,李天女,范磊,等.肺大细胞神经内分泌癌的18F-FDG PET/CT表现[J].国际放射医学核医学杂志,2018,(6):486.[doi:10.3760/cma.j.issn.1673-4114.2018.06.002]
Liu Wei,Li Tiannyu,Fan Lei,et al.18F-FDG PET/CT manifestations of pulmonary large cell neuroendocrine carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(4):486.[doi:10.3760/cma.j.issn.1673-4114.2018.06.002]